8-K: Enfusion Acquired by Clearwater Analytics, Completes Merger

Enfusion, Inc. has completed its merger with Clearwater Analytics Holdings, Inc., resulting in Enfusion becoming a wholly-owned subsidiary of Clearwater.

Summary

• Enfusion, Inc. and Clearwater Analytics Holdings, Inc. completed their merger on April 21, 2025.
• Enfusion is now a wholly-owned subsidiary of Clearwater.
• The merger was approved by Enfusion's stockholders on April 17, 2025.
• Holders of Enfusion Common Stock, Enfusion Vested RSUs, and Enfusion Common Units had the option to receive cash, Clearwater Common Stock, or a combination thereof, subject to proration.
• The Per Share Cash Consideration option was oversubscribed and subject to proration, with approximately 52% of Eligible Shares receiving cash consideration and 48% receiving stock consideration.
• The Final Parent Stock Price as of April 16, 2025, was $23.2440, resulting in a Per Share Parent Stock Amount of 0.2159, an Aggregate Consideration of $1,412,840,049.03, an Aggregate Consideration Per Share of $10.87, and an Exchange Ratio of 0.4676.
• Enfusion's Class A Common Stock was delisted from the New York Stock Exchange (NYSE) on April 21, 2025.
• Outstanding Enfusion equity-based awards were treated as follows: In-the-Money Enfusion Options were cancelled in exchange for cash, Enfusion Vested RSUs were cancelled in exchange for the merger consideration, Enfusion Unvested RSUs were assumed by Clearwater and converted into Assumed RSUs, and Enfusion PSUs that vested as a result of the merger were cancelled and converted into the right to receive the Per Share Mixed Consideration.
• All loans and other obligations outstanding under the Credit Agreement were repaid and the credit facilities thereunder were terminated.

Sentiment

Score: 7

Explanation: The document is factual and reports the completion of a merger. The sentiment is neutral to positive, as the merger is presented as a completed transaction with defined terms for stockholders.

Positives

• The merger provides Enfusion stockholders with liquidity through cash and/or Clearwater Common Stock.
• Clearwater assumes Enfusion's unvested equity awards, providing continued incentives for employees.
• The completion of the merger eliminates Enfusion's debt under the Credit Agreement.

Negatives

• Enfusion's Class A Common Stock is no longer publicly traded, removing the opportunity for future independent growth.
• The Per Share Cash Consideration option was oversubscribed, leading to proration and potentially less cash for some stockholders than initially desired.
• Enfusion PSUs that did not vest at the Effective Time were cancelled as of the Effective Time for no consideration.

Risks

• The integration of Enfusion into Clearwater may present challenges.
• Proration of the cash consideration could lead to dissatisfaction among some Enfusion stockholders.
• The value of the Clearwater Common Stock received as part of the merger consideration could fluctuate.

Future Outlook

Enfusion will operate as a wholly-owned subsidiary of Clearwater Analytics. The document does not provide specific forward-looking statements regarding the combined company's performance.

Industry Context

The acquisition of Enfusion by Clearwater Analytics reflects a trend of consolidation in the financial technology sector, as companies seek to expand their product offerings and market reach.

Comparison to Industry Standards

• Comparable transactions in the financial technology sector include Vista Equity Partners' acquisition of Avaloq and Thoma Bravo's acquisition of Calypso Technology.
• These deals often involve larger players acquiring smaller, specialized firms to enhance their capabilities and customer base.
• The valuation metrics in this deal, such as the Aggregate Consideration Per Share, can be compared to those of similar transactions to assess its relative value.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders received cash and/or stock in Clearwater Analytics.
• Employees with unvested equity awards will have them assumed by Clearwater Analytics.
• Customers will likely see integration of Enfusion's products and services into Clearwater's broader platform.

Next Steps

• Enfusion will operate as a wholly-owned subsidiary of Clearwater Analytics.
• Clearwater will integrate Enfusion's operations and technology.
• Enfusion intends to file with the SEC a Form 15 under the Exchange Act requesting deregistration of the Enfusion Common Stock under Section 12(g) of the Exchange Act and suspension of Enfusions reporting obligations under Section 13 and Section 15(d) of the Exchange Act.

Key Dates

Keywords

merger, acquisition, Clearwater Analytics, Enfusion, delisting, NYSE, stockholders, consideration, equity awards